🔗 Permalink

Inventor profile of:

Philip E. Brandish

City:

Needham, Massachusetts

Country:

United States

Published Applications:

Last publication date:

2026-06-18

Top Assignees for applications by Philip E. Brandish

The entities that hold a legal rights for patent applications filed by inventor Brandish Philip E.:

Merck Sharp Dohme Corp. 9 Rahway, NJ United States
Merck Sharp & Dohme LLC 7 Rahway, NJ United States
Merck Sharp & Dohme LLC 4 Rahway, NJ United States
AMBRX, INC. 3 La Jolla, CA United States
Eisai R&D Management Co., Ltd. 1 Bunkyo-ku, Tokyo, Japan
BicycleTx Limited 1 Cambridge, United Kingdom

Recent patent applications by Brandish Philip E.

Philip E. Brandish from Needham, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-06-18

US20260167718A1

Chemistry; metallurgy

ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF

#2 | 2025-06-12

US20250186539A2

Human necessities

METHODS FOR TREATING CANCER

#3 | 2024-10-03

US20240325554A1

Human necessities

METHODS FOR TREATING CANCER

#4 | 2024-09-26

US20240317854A1

Chemistry; metallurgy

METHODS FOR TREATING CANCER WITH ANTI-ILT3 ANTIBODIES

#5 | 2023-05-11

US20230147502A1

Human necessities

Phosphonate linkers and their use to facilitate cellular retention of compounds

#6 | 2023-03-30

US20230099074A1

Human necessities

ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS

#7 | 2023-02-23

US20230058779A1

Human necessities

COMBINATION CANCER TREATMENT USING A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND LENVATINIB OR SALTS THEREOF

#8 | 2023-02-16

US20230050449A1

Chemistry; metallurgy

METHODS FOR TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPEUTIC AGENTS

#9 | 2022-02-03

US20220033497A1

Chemistry; metallurgy

ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF

#10 | 2022-01-27

US20220025043A1

Chemistry; metallurgy

ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF

#11 | 2022-01-27

US20220025042A1

Chemistry; metallurgy

ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF

#12 | 2022-01-13

US20220010011A1

Chemistry; metallurgy

ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF

#13 | 2022-01-13

US20220010010A1

Chemistry; metallurgy

ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF

#14 | 2021-01-21

US20210015930A1

Human necessities

Phosphonate linkers and their use to facilitate cellular retention of compounds

#15 | 2020-05-28

US20200164085A1

Human necessities

Antibody drug conjugate for anti-inflammatory applications

#16 | 2019-05-23

US20190153093A1

Chemistry; metallurgy

Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof

#17 | 2019-01-31

US20190030171A1

Human necessities

Phosphonate linkers and their use to facilitate cellular retention of compounds

#18 | 2017-06-29

US20170182181A1

Human necessities

Phosphate based linkers for intracellular delivery of drug conjugates

InventorID:

1914597 ⎘